{"DataElement":{"publicId":"6596648","version":"1","preferredName":"Prior Chemotherapy Trastuzumab Administered Neoadjuvant Therapy Trastuzumab Type","preferredDefinition":"information related to earlier in time or order administration of treatment with anticancer drug Trastuzumab (a humanized recombinant monoclonal antibody directed against the HER2- receptor protein)._The administration of therapeutic agents prior to the primary treatment for the purpose of making the primary treatment more effective._A recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). After binding to HER2 on the tumor cell surface, trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2. HER2 is overexpressed by many adenocarcinomas, particularly breast adenocarcinomas. (NCI04)_Something distinguishable as an identifiable class based on common qualities.","longName":"P_CTX_TRAST_ADMIN_6596645v1.0","context":"NRG","contextVersion":"1","DataElementConcept":{"publicId":"2493778","version":"1","preferredName":"Prior Chemotherapy Trastuzumab Administered","preferredDefinition":"information related to earlier in time or order administration of treatment with anticancer drug Trastuzumab (a humanized recombinant monoclonal antibody directed against the HER2- receptor protein).","longName":"P_CTX_TRAST_ADMIN","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2206391","version":"1","preferredName":"Prior Chemotherapy","preferredDefinition":"Earlier in time or order.:The use of synthetic or naturally-occurring chemicals for the treatment of diseases.  Although this term may be used to describe any therapy involving the use of chemical-based agents, it is most commonly used to refer to the variety of chemical-based agents employed to treat cancer.  Cancer chemotherapy works by arresting or killing the growth and spread of cancer cells.  Because cancer cells usually divide much faster than normal cells, they are often very sensitive to the inhibitory actions of chemotherapeutic agents.  Chemotherapy may also include agents that enhance immune function or alter hormonal activity. (NCI04)","longName":"C25629:C15632","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Chemotherapy","conceptCode":"C15632","definition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0428-F3A3-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2493776","version":"1","preferredName":"Trastuzumab Administered","preferredDefinition":"A humanized recombinant monoclonal antibody directed against the HER2- receptor protein.  Trastuzumab binds to the extracellular domain of the growth factor protein HER2, thereby inhibiting proliferation of HER2 overexpressing tumor cells.  Binding with HER2 protein also initiates an antibody-dependent cell cytotoxicity.(NCI):Given.","longName":"C1647:C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trastuzumab","conceptCode":"C1647","definition":"A recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). After binding to HER2 on the tumor cell surface, trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2. HER2 is overexpressed by many adenocarcinomas, particularly breast adenocarcinomas. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"17979168-D0E6-34D3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-02","endDate":null,"createdBy":"ALAIS","dateCreated":"2006-07-02","modifiedBy":"ONEDATA","dateModified":"2006-07-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"17979168-D0F7-34D3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-02","endDate":null,"createdBy":"ALAIS","dateCreated":"2006-07-02","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6596645","version":"1","preferredName":"Neoadjuvant Therapy Trastuzumab Type","preferredDefinition":"The administration of therapeutic agents prior to the primary treatment for the purpose of making the primary treatment more effective._A recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). After binding to HER2 on the tumor cell surface, trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2. HER2 is overexpressed by many adenocarcinomas, particularly breast adenocarcinomas. (NCI04)_Something distinguishable as an identifiable class based on common qualities.","longName":"6596645v1.0","context":"NRG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":null,"minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Yes, with either pertuzumab or delayed adjuvant neratinib","valueDescription":"Yes, with either pertuzumab or delayed adjuvant neratinib","ValueMeaning":{"publicId":"6596646","version":"1","preferredName":"Yes, with either pertuzumab or delayed adjuvant neratinib","longName":"6596646","preferredDefinition":"Yes, with either pertuzumab or delayed adjuvant neratinib","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7D63AA81-AE20-301A-E053-F662850AA536","latestVersionIndicator":"Yes","beginDate":"2018-12-19","endDate":null,"createdBy":"SARAHB","dateCreated":"2018-12-19","modifiedBy":"ONEDATA","dateModified":"2018-12-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7D63AA81-AE39-301A-E053-F662850AA536","beginDate":"2018-12-19","endDate":null,"createdBy":"SARAHB","dateCreated":"2018-12-19","modifiedBy":"ONEDATA","dateModified":"2018-12-19","deletedIndicator":"No"},{"value":"Yes, with neither pertuzumab or delayed adjuvant neratinib","valueDescription":"Yes, with neither pertuzumab or delayed adjuvant neratinib","ValueMeaning":{"publicId":"6596647","version":"1","preferredName":"Yes, with neither pertuzumab or delayed adjuvant neratinib","longName":"6596647","preferredDefinition":"Yes, with neither pertuzumab or delayed adjuvant neratinib","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7D63AA81-AE43-301A-E053-F662850AA536","latestVersionIndicator":"Yes","beginDate":"2018-12-19","endDate":null,"createdBy":"SARAHB","dateCreated":"2018-12-19","modifiedBy":"ONEDATA","dateModified":"2018-12-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7D63AA81-AE5C-301A-E053-F662850AA536","beginDate":"2018-12-19","endDate":null,"createdBy":"SARAHB","dateCreated":"2018-12-19","modifiedBy":"ONEDATA","dateModified":"2018-12-19","deletedIndicator":"No"},{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3216924","version":"1","preferredName":"No","longName":"3216924v1.00","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9FB8B94D-C670-2CB0-E040-BB89AD4377A2","latestVersionIndicator":"Yes","beginDate":"2011-03-30","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2011-03-30","modifiedBy":"KUMMEROA","dateModified":"2022-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7D63AA81-AE66-301A-E053-F662850AA536","beginDate":"2018-12-19","endDate":null,"createdBy":"SARAHB","dateCreated":"2018-12-19","modifiedBy":"ONEDATA","dateModified":"2018-12-19","deletedIndicator":"No"},{"value":"Yes with neither pertuzumab or delayed adjuvant neratinib","valueDescription":"Yes with neither pertuzumab or delayed adjuvant neratinib","ValueMeaning":{"publicId":"6661089","version":"1","preferredName":"Yes with neither pertuzumab or delayed adjuvant neratinib","longName":"6661089","preferredDefinition":"Yes with neither pertuzumab or delayed adjuvant neratinib","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8348DE28-0AD4-5F7F-E053-F662850A9A39","latestVersionIndicator":"Yes","beginDate":"2019-03-04","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2019-03-04","modifiedBy":"ONEDATA","dateModified":"2019-03-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8348DE28-0AED-5F7F-E053-F662850A9A39","beginDate":"2019-03-04","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2019-03-04","modifiedBy":"ONEDATA","dateModified":"2019-03-04","deletedIndicator":"No"},{"value":"Yes with either pertuzumab or delayed adjuvant neratinib","valueDescription":"Yes with either pertuzumab or delayed adjuvant neratinib","ValueMeaning":{"publicId":"6661090","version":"1","preferredName":"Yes with either pertuzumab or delayed adjuvant neratinib","longName":"6661090","preferredDefinition":"Yes with either pertuzumab or delayed adjuvant neratinib","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8348DE28-0AF7-5F7F-E053-F662850A9A39","latestVersionIndicator":"Yes","beginDate":"2019-03-04","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2019-03-04","modifiedBy":"ONEDATA","dateModified":"2019-03-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8348DE28-0B10-5F7F-E053-F662850A9A39","beginDate":"2019-03-04","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2019-03-04","modifiedBy":"ONEDATA","dateModified":"2019-03-04","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C55CAF6D-61BF-6346-E053-4EBD850A9198","beginDate":"2021-06-22","endDate":null,"createdBy":"BOWSERC","dateCreated":"2021-06-22","modifiedBy":"ONEDATA","dateModified":"2021-06-22","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6596644","version":"1","preferredName":"Neoadjuvant Therapy Trastuzumab Type","preferredDefinition":"The administration of therapeutic agents prior to the primary treatment for the purpose of making the primary treatment more effective.:A recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). After binding to HER2 on the tumor cell surface, trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2. HER2 is overexpressed by many adenocarcinomas, particularly breast adenocarcinomas. (NCI04):Something distinguishable as an identifiable class based on common qualities.","longName":"C15665:C1647:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neoadjuvant Therapy","conceptCode":"C15665","definition":"Therapy administered prior to the primary treatment for the purpose of making the primary treatment more effective.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Trastuzumab","conceptCode":"C1647","definition":"A recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). After binding to HER2 on the tumor cell surface, trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2. HER2 is overexpressed by many adenocarcinomas, particularly breast adenocarcinomas. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7D63AA81-ADFB-301A-E053-F662850AA536","latestVersionIndicator":"Yes","beginDate":"2018-12-19","endDate":null,"createdBy":"SARAHB","dateCreated":"2018-12-19","modifiedBy":"ONEDATA","dateModified":"2018-12-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7D63AA81-AE0C-301A-E053-F662850AA536","latestVersionIndicator":"Yes","beginDate":"2018-12-19","endDate":null,"createdBy":"SARAHB","dateCreated":"2018-12-19","modifiedBy":"BOWSERC","dateModified":"2021-06-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Prior Neoadjuvant or Adjuvant","type":"Preferred Question Text","description":"Prior Neoadjuvant or Adjuvant Therapy with Trastuzumab:","url":null,"context":"NRG"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7D63AA81-AE72-301A-E053-F662850AA536","latestVersionIndicator":"Yes","beginDate":"2018-12-19","endDate":null,"createdBy":"SARAHB","dateCreated":"2018-12-19","modifiedBy":"SARAHB","dateModified":"2019-01-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}